about
Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the MythsThe impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature reviewThe comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia.Ziprasidone: the fifth atypical antipsychotic.Fatal diabetic ketoacidosis and antipsychotic medication.The effects of atypical antipsychotic usage duration on serum adiponectin levels and other metabolic parameters.Atypical antipsychotics for acute agitation. New intramuscular options offer advantages.A review of olanzapine-associated toxicity and fatality in overdose.A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.Atypical antipsychotics and diabetes mellitus.Safety and tolerability of emerging pharmacological treatments for bipolar disorder.Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes.The impact of weight gain associated with atypical antipsychotic use in schizophrenia.Atypical antipsychotics: revolutionary or incremental advance?Subthalamic nucleus stimulation does not influence basal glucose metabolism or insulin sensitivity in patients with Parkinson's disease.Incidence of diabetes in patients with schizophrenia: a population-based study.Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.Glucose Disturbances and Atypical Antipsychotic Use in the Intensive Care Unit.Olanzapine induced biochemical and histopathological changes after its chronic administration in rats.Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults.Modulating effects of olanzapine on the development of diabetic ketoacidosis.Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.Quetiapine in the successful treatment of psychosis and comorbid brittle diabetes mellitus: a case report.Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Quality of life issues associated with antipsychotic-induced weight gain.Clinical features of bipolar disorder with and without comorbid diabetes mellitus.Consequences of Undocumented Medication Use.Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.Clozaphobia: Fear of Prescribers of Clozapine for Treatment of Schizophrenia
P2860
Q24596954-FDC43798-FF50-44C9-9ACC-72F998A4273AQ33924804-931F6899-D0EC-4479-B9FB-8F9BBB381E12Q33968686-0964795B-F194-400E-9138-24262DA85DADQ34615595-D50CC481-9D64-4C9B-8847-62DBBFC82528Q34646940-D1AEB3C3-75C8-4D27-9C99-19BFE45631ADQ34666581-9EF3E08D-69C7-4778-B17A-A8C4CAA99FBAQ35037851-5A046A3F-CBAF-4836-9A43-259FA53347B7Q35162502-779564A6-2473-43C6-817E-902DB684AB04Q35666903-F4D410C4-62E5-4871-94B1-8C421802726CQ35752734-12FC7994-E19B-49EE-AE43-F11BF2953F14Q35793345-4696B5E9-CEF4-4B0F-A590-180D8D0E0CDCQ36199036-4BAAECED-EEDE-4BD1-B2DA-33E1FF619431Q37959292-231379EE-F7AD-424A-B37F-2E552FC996DAQ38777526-2C69C91C-5200-4290-A821-B61E5919BA59Q39412178-CAB3E897-A6F2-4B9B-B701-70D05CA96EBDQ39528966-F03655AD-6908-49C6-95E0-5C9AAA75DB08Q39971247-B98C18A1-BAE1-41B9-83B3-3748203F6766Q40380108-5E5F53D6-070B-4A41-8AAD-3E55178208E3Q40963710-CBD85F47-099F-4D33-9777-4F7E660F3E14Q41663843-70958309-CB63-49FE-BF0B-F6CFB4849601Q43294341-F3B73819-869D-4D16-BA31-B23257A0906AQ44207549-F938A9A0-439E-43D1-8DE4-5293630D2976Q44657170-C7E51AB0-5B42-4B7E-8CD1-17CECD2F0548Q44791695-C09D58CC-F949-4DAC-A1FD-54EEE775C818Q44858920-6A882852-B109-4233-8C62-1326857DE240Q44902733-CC2FA3BE-4A4E-4A0B-91C2-4BB27FC694E7Q45235733-116F4E4C-DEB1-401E-BE06-2C0EAEE2484FQ46939700-EAAC5B57-B19C-4347-B599-DFCA6F3C50E6Q47441133-D7B89AD6-09BE-40FD-B103-286603A6A2BBQ47629610-FA806CAB-0096-4C16-92AD-2EA9BF9BB7ECQ49885361-F9A8733E-EC60-47A5-B3B7-1E1E3CA9A2D8Q51487515-E25F71A4-94F1-4C53-9B40-029019167CF8Q57820263-FF097C73-E5FB-4C84-8897-34B6A6258BE0
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
New onset diabetes and atypical antipsychotics.
@ast
New onset diabetes and atypical antipsychotics.
@en
type
label
New onset diabetes and atypical antipsychotics.
@ast
New onset diabetes and atypical antipsychotics.
@en
prefLabel
New onset diabetes and atypical antipsychotics.
@ast
New onset diabetes and atypical antipsychotics.
@en
P2093
P1476
New onset diabetes and atypical antipsychotics.
@en
P2093
Liebzeit KA
Markowitz JS
P356
10.1016/S0924-977X(00)00127-9
P407
P577
2001-02-01T00:00:00Z